CR20110368A - Compuestos de quinazolina sustituidos - Google Patents

Compuestos de quinazolina sustituidos

Info

Publication number
CR20110368A
CR20110368A CR20110368A CR20110368A CR20110368A CR 20110368 A CR20110368 A CR 20110368A CR 20110368 A CR20110368 A CR 20110368A CR 20110368 A CR20110368 A CR 20110368A CR 20110368 A CR20110368 A CR 20110368A
Authority
CR
Costa Rica
Prior art keywords
methods
substituted quinazoline
quinazoline compounds
compounds
kinase
Prior art date
Application number
CR20110368A
Other languages
English (en)
Spanish (es)
Inventor
Caroline Leriche
Eric Auclair
Roux Jacques Le
David N Middlemiss
Original Assignee
Fovea Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41735344&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20110368(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fovea Pharmaceuticals filed Critical Fovea Pharmaceuticals
Publication of CR20110368A publication Critical patent/CR20110368A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CR20110368A 2008-12-29 2011-06-27 Compuestos de quinazolina sustituidos CR20110368A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08360043 2008-12-29

Publications (1)

Publication Number Publication Date
CR20110368A true CR20110368A (es) 2011-12-02

Family

ID=41735344

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20110368A CR20110368A (es) 2008-12-29 2011-06-27 Compuestos de quinazolina sustituidos

Country Status (23)

Country Link
US (1) US8389530B2 (enExample)
EP (1) EP2381943A1 (enExample)
JP (1) JP2012514020A (enExample)
KR (1) KR20110120878A (enExample)
CN (1) CN102333533A (enExample)
AU (1) AU2009334869A1 (enExample)
BR (1) BRPI0924067A2 (enExample)
CA (1) CA2748319A1 (enExample)
CO (1) CO6390105A2 (enExample)
CR (1) CR20110368A (enExample)
DO (1) DOP2011000209A (enExample)
EA (1) EA019110B1 (enExample)
EC (1) ECSP11011204A (enExample)
IL (1) IL213742A0 (enExample)
MA (1) MA32968B1 (enExample)
MX (1) MX2011007064A (enExample)
NI (1) NI201100134A (enExample)
NZ (1) NZ593949A (enExample)
PE (1) PE20120424A1 (enExample)
SG (1) SG172415A1 (enExample)
TN (1) TN2011000319A1 (enExample)
WO (1) WO2010076238A1 (enExample)
ZA (1) ZA201104777B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR081960A1 (es) 2010-06-22 2012-10-31 Fovea Pharmaceuticals Sa Compuestos heterociclicos, su preparacion y su aplicacion terapeutica
US8802697B2 (en) 2012-07-11 2014-08-12 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
AU2014339972B9 (en) 2013-10-25 2019-05-30 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
WO2015108992A1 (en) 2014-01-15 2015-07-23 Blueprint Medicines Corporation Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
KR101715448B1 (ko) * 2014-07-16 2017-03-20 주식회사 큐리언트 염증성 질환 치료용 화합물
SG11201705192PA (en) 2014-12-24 2017-07-28 Gilead Sciences Inc Fused pyrimidine compounds for the treatment of hiv
TWI770552B (zh) 2014-12-24 2022-07-11 美商基利科學股份有限公司 喹唑啉化合物
ES2705709T3 (es) 2014-12-24 2019-03-26 Gilead Sciences Inc Compuestos de isoquinolina para el tratamiento del VIH
CN112239459B (zh) * 2019-07-19 2021-11-26 中国科学院上海药物研究所 稠环嘧啶氨基化合物、其制备方法、药物组合物及应用
CN115916759B (zh) * 2020-06-19 2025-07-15 泰州红云制药有限公司 取代喹唑啉类化合物、其制备方法、药物组合及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0015718A (pt) 1999-11-22 2002-07-23 Warner Lambert Co Quinazolinas e seu uso para inibição de enzimas de cinase dependente de ciclina
WO2004065378A1 (en) 2003-01-17 2004-08-05 Warner-Lambert Company Llc 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
CA2542329A1 (en) 2003-10-16 2005-04-28 Chiron Corporation 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of raf kinase for treatment of cancer
NZ551027A (en) 2004-04-08 2011-01-28 Targegen Inc Benzotriazine inhibitors of kinases
JP5275628B2 (ja) 2004-08-25 2013-08-28 ターゲジェン インコーポレーティッド 複素環式化合物および使用方法
US20070054916A1 (en) * 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
CN101155799A (zh) 2005-03-16 2008-04-02 塔格根公司 嘧啶化合物和使用方法
US7906522B2 (en) * 2005-04-28 2011-03-15 Kyowa Hakko Kirin Co., Ltd 2-aminoquinazoline derivatives
AU2006254825A1 (en) 2005-06-08 2006-12-14 Targegen, Inc. Methods and compositions for the treatment of ocular disorders
AR060358A1 (es) * 2006-04-06 2008-06-11 Novartis Vaccines & Diagnostic Quinazolinas para la inhibicion de pdk 1
JP2010514693A (ja) * 2006-12-22 2010-05-06 ノバルティス アーゲー Pdk1阻害のためのキナゾリン

Also Published As

Publication number Publication date
AU2009334869A1 (en) 2011-07-14
BRPI0924067A2 (pt) 2016-01-26
DOP2011000209A (es) 2011-09-30
MX2011007064A (es) 2012-01-20
EA019110B1 (ru) 2014-01-30
NZ593949A (en) 2013-08-30
TN2011000319A1 (en) 2012-12-17
PE20120424A1 (es) 2012-05-04
IL213742A0 (en) 2011-07-31
JP2012514020A (ja) 2012-06-21
WO2010076238A1 (en) 2010-07-08
ZA201104777B (en) 2012-03-28
EP2381943A1 (en) 2011-11-02
KR20110120878A (ko) 2011-11-04
AU2009334869A2 (en) 2011-09-29
EA201101012A1 (ru) 2012-01-30
ECSP11011204A (es) 2011-10-31
NI201100134A (es) 2012-03-06
US8389530B2 (en) 2013-03-05
US20120004210A1 (en) 2012-01-05
CA2748319A1 (en) 2010-07-08
SG172415A1 (en) 2011-07-28
CO6390105A2 (es) 2012-02-29
MA32968B1 (fr) 2012-01-02
CN102333533A (zh) 2012-01-25

Similar Documents

Publication Publication Date Title
CR20110368A (es) Compuestos de quinazolina sustituidos
CR20110386A (es) 1, 2, 4] triazolo [1, 5 -a] piridinas como inhibidores de cinasa
CR20110103A (es) Heteroarilos sustituidos
UY37018A (es) Inhibidores bicíclicos de pad4
MX2012013256A (es) Composiciones y metodos para el tratamiento de leucemia.
UA111075C2 (uk) Триазолопіридинові сполуки як інгібітори кінази рім
AU2011278832A8 (en) Novel fused heterocyclic derivatives useful as c-Met tyrosine kinase inhibitors
NZ598516A (en) Quinazolines as potassium ion channel inhibitors
CR10995A (es) Inhibidores de la actividad de akt
EA201171367A1 (ru) Винилиндазолильные соединения
EA200901144A1 (ru) Ингибиторы киназы pim и способы их применения
EA201071089A1 (ru) Производные хиназолина как модуляторы raf-киназы и способы их применения
ECSP12011982A (es) Aminopirimidinas como inhibidores de syk
TN2014000093A1 (en) Method of treating gastrointestinal stromal tumors
EA201170699A1 (ru) Тетразамещенные пиридазины в качестве антагонистов пути hedgehog
ECSP12012354A (es) Compuestos heterocíclicos, su preparación y su aplicación terapéutica
EA201170288A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
UY32214A (es) Agonistas del receptor s1p para el tratamiento de malaria cerebral
UY32291A (es) Inhibidores de quinasa con perfiles de seguridad cyp mejorados
MX2010005395A (es) Metodo para tratar artritis.
EA201170831A1 (ru) Аминопиразольное соединение
PH12015500363A1 (en) Prodrugs of amino quinazoline kinase inhibitor
BR112012020585A2 (pt) composto, composição farmacêutica e método de tratamento de um distúrbio mediado por tirosina quinase
BRPI0822012A2 (pt) Derivados de quinazolina de 6,7-dialcóxi úteis para o tratamento de distúrbios relacionados com câncer
IN2014CN04050A (enExample)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)